tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

IceCure Medical Announces Special General Meeting for Director Appointment

Story Highlights
IceCure Medical Announces Special General Meeting for Director Appointment

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Icecure Medical ( (ICCM) ) just unveiled an update.

IceCure Medical Ltd. has announced a Special General Meeting of Shareholders scheduled for September 1, 2025, to appoint Mr. Yonatan Malca as an external director for a three-year term. Shareholders of record as of August 4, 2025, are eligible to vote on the proposal, which the Board of Directors unanimously recommends. The meeting will be held remotely, and shareholders can vote either in person or by proxy. This meeting is significant as it involves the appointment of a new director, which could influence the company’s strategic direction and governance.

The most recent analyst rating on (ICCM) stock is a Buy with a $2.50 price target. To see the full list of analyst forecasts on Icecure Medical stock, see the ICCM Stock Forecast page.

Spark’s Take on ICCM Stock

According to Spark, TipRanks’ AI Analyst, ICCM is a Neutral.

Icecure Medical’s stock score is primarily influenced by its ongoing financial challenges, reflected in its negative profitability and cash flow issues. Despite these challenges, technical analysis indicates some positive momentum, and positive developments from the earnings call, including FDA progress and interest from the medical community, provide potential upside. However, valuation remains a concern with negative earnings.

To see Spark’s full report on ICCM stock, click here.

More about Icecure Medical

IceCure Medical Ltd. operates in the medical industry, focusing on the development and commercialization of minimally invasive cryoablation therapies for treating tumors. The company’s primary product is the ProSense system, which is used in the treatment of breast, lung, and other cancers. IceCure Medical is headquartered in Caesarea, Israel, and is listed on the Nasdaq Stock Market.

Average Trading Volume: 958,526

Technical Sentiment Signal: Hold

Current Market Cap: $73.5M

For a thorough assessment of ICCM stock, go to TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1